Biggest S&P 500 winners and losers of 2017: Tech, health care and home builders lead General Electric, energy companies suffered in 2017Tech companies and home builders figure prominently in the best performing stocks of 2017 on the S&P 500 index, while energy companies and a few retail and consumer stocks figure among the worst performers.

Proteostasis Therapeutics shares down 8% after proposed share offeringShares of Proteostasis Therapeutics Inc. fell more than 8% in the late session Tuesday after the company said it plans to sell 7 million shares of its common stock. Underwriters will have a 30-day option to buy up to 1.05 million additional shares, the company said. Proteostasis on Monday announced , lifting shares earlier Tuesday. Proteostasis' shares ended the regular Tuesday session up 161%. The shares are down 50% this year, compared with gains of 19% for the S&P 500 index.

Proteostasis Therapeutics' stock nearly doubles on heavy volume after positive trial resultsShares of Proteostasis Therapeutics Inc. nearly doubled in active premarket trade Tuesday, after the developer of cystic fibrosis treatments announced positive results from three trials. The company phase 2 trial of 50 milligram-a-day of PTI-428 in patients on background Orkambi met its efficacy endpoint. "This is an important first step towards translating the scientific potential of the first and only genotype agnostic CFTR modulator in development, and its ability to enhance Orkambi by selectively increasing the production of the CFTR protein," said Patrick Flume, a clinical investigator at the Medical University of South Carolina. Separtely, a preliminary ad hoc analysis of PTI-801 showed improvements without serious adverse safety events, and PTI-808 was found in a healthy volunteer co-administration study to be well tolerated and could be potentially amenable to once-a-day dosing. The stock shot up 86% on volume of over 484,000 shares about two hours before the open, compared with the full-day average volume of about 193,100 shares. The stock has plunged 81% year to date through Monday, while the iShares Nasdaq Biotechnology ETF has rallied 20% and the S&P 500 has gained 19%.

Six promising stocks to buy for the biotech rebound ahead A big selloff last week clears the way for buying opportunitiesA big selloff last week clears the way for buying opportunities, says Michael Brush.

Health-care fund managers say a spike in drugs and devices will produce big returns Higher-quality applications to the FDA could ignite health-care stocks, according to the managers of the Janus Henderson Global Life Sciences Fund Higher-quality applications to the FDA could ignite health-care stocks, according to the managers of the Janus Henderson Global Life Sciences Fund.

Vertex stock rockets to record, boosting market cap by $8 billion Shares run up 24% as cystic fibrosis drug shows promiseVertex Pharmaceuticals Inc. shares soared, adding over $8 billion to the company’s value, as the biotech drug maker announced positive results from clinical studies of its cystic fibrosis treatments, and boosted the company’s probability of becoming a buyout target, according to one analyst.

S&P 500, Nasdaq at all-time highs after opening gainsThe S&P 500, Nasdaq Composite traded in record territory shortly after the opening bell. But the gains on Wall Street were small as investors focused on a batch of mixed earnings reports. The S&P 500 was up by 4 points, or 0.2%, to 2,464.63. The Dow Jones Industrial Average was up fractionally at 21,581. The Nasdaq Composite index advanced 21 points, or 0.3%, to 6,368. Among early movers, Vertex Pharmaceuticals Inc. soared 23% after the drug company late Tuesday announced positive results from clinical studies of its cystic fibrosis treatments.

Vertex Pharma shares rally on cystic fibrosis drug study resultsVertex Pharmaceuticals Inc. shares surged in the extended session Tuesday after the biotech drug maker announced positive results from clinical trials of its cystic fibrosis treatments. Vertex shares rallied 26% to $166.50 after hours. The company said data from clinical studies of its treatment candidates VX-152 and VX-440 showed an up to 12% average improvement in lung function in cystic fibrosis patients given the drugs. Cystic fibrosis is a genetic defect that causes an abnormal buildup of mucus in the lungs leading to chronic infection and progressive lung damage.

Vertex shares up more than 1% after FDA drug approvalShares of Vertex Pharmaceuticals Inc. rose more than 1% late Wednesday after the company said the U.S. Food and Drug Administration has approved one of its drugs for the treatment of certain mutations of the gene that causes cystic fibrosis. The company increased its sales expectations for the drug, called Kalydeco, to between $740 million and $770 million this year. Vertex said it is continuing to talk with the FDA about approving the drug to other mutations. The shares had ended the regular session down 3.1%.

These corporate ties will be on display at Scott Gottlieb’s FDA commissioner confirmation hearing today Gottlieb has taken more than $400,000 from drugmakers in the last few yearsThe previous FDA commissioner was criticized for taking large fees from companies.

Vertex Pharma shares soar 21% as company ups its cystic fibrosis offerings The combination treatment seems to work better than and lacks the side effects of Vertex’s Orkambi Wall Street analysts were unusually impressed by the Tuesday results from a trial of a cystic fibrosis treatment.

Vertex to seek approval of new cystic-fibrosis drug Experimental drug showed promise in latest studyVertex Pharmaceuticals Inc. said it would seek regulatory approval for one of its experimental cystic-fibrosis drugs after the treatment helped improve patients’ lung function in late-stage studies.

Vertex Pharma shares jump more than 20% on cystic fibrosis study resultsVertex Pharmaceuticals Inc. shares surged in the extended session Tuesday after the biotech drug maker said its cystic fibrosis treatment met endpoints in two late-stage clinical studies. Vertex shares rose 6.3% to $95.30 after hours, before being halted. As after-hours trading resumed, shares surged 21% to $108.60. The company said two studies showed its combination treatment of the drug tezacaftor and its branded drug Kalydeco significantly improved the lung function in cystic fibrosis patients. Vertex said it plans to submit marketing applications based on the results to both the U.S. Food and Drug Administration and the European Medicines Agency in the third quarter.

Harry Boxer’s six biotechnology stocks to watch TG Therapeutics, Concert Pharmaceuticals, Kite Pharma and three other companies soared as much as 90% TG Therapeutics, Concert Pharmaceuticals, Kite Pharma and three other companies soared as much as 90%.

Concert Pharma shares rally 34% on news Vertex to pay up to $250 million for cystic fibrosis drugShares of Concert Pharmaceuticals Inc. rallied 34% premarket Monday, after the company said Vertex Pharmaceuticals Inc. is buying its cystic fibrosis treatment CTP-656 and other assets in a deal worth up to $250 million. Vertex will pay Concert $160 million in cash on deal closing for the development and selling rights to CTP-656. Vertex will pay up to an additional $90 million in milestone payments, if the treatment is approved as part of a combination regime for cystic fibrosis in the U.S. and approved for reimbursement in the U.K, Germany or France. The drug is currently in Phase II trials with data expected by year-end. Concert made the announcement as it reported results for 2016, showing a loss of $50.7 million, or $2.28 a share, after earnings of $24.2 million, or $1.09 a share, in the year-earlier period. Revenue fell sharply to $174,000 from $66.7 million the year earlier, when it was boosted by a one-time $50.2 million change of control payment from Auspex Pharma, which was a result of their being acquired by Teva Pharmaceuticals Ltd. . The company said it had $96.2 million in cash and cash equivalents at the end of the year and expects that to be enough to fund operations through the second quarter of 2018. Shares are down 28% in the last 12 months, while the S&P 500 has gained 19%.

Could your Fitbit data raise the cost of your health insurance? Soon, wearable health devices may be able to diagnose illnessesWearable health devices may soon be able to diagnose illnesses. How will insurance companies use the data?

Intraday Data provided by SIX Financial Information and subject to terms of use. Historical and current end-of-day data provided by SIX Financial Information. All quotes are in local exchange time. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements.